Drug Trial News

RSS

Novartis reports positive results from first pivotal ACZ885 Phase III trial in systemic juvenile idiopathic arthritis

Novartis announced today positive results of the first pivotal Phase III trial of ACZ885 in patients with systemic juvenile idiopathic arthritis (SJIA), a rare and serious childhood auto-inflammatory disease. The results, presented at the 2011 European Pediatric Rheumatology Congress in Bruges, Belgium, showed all primary and secondary endpoints of the study were met.

17 Sep 2011

Additional data on safety, tolerability of Cempra's solithromycin to be presented at 51st ICAAC

Cempra Pharmaceuticals today announced abstracts to be presented on its fourth generation macrolide and novel fluoroketolide antibiotic, solithromycin (CEM-101), at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), September 17 to 20, 2011, in Chicago. The abstracts provide additional data that demonstrate the safety and routes of administration of CEM-101, a new generation macrolide.

17 Sep 2011

Multiple abstracts on QNEXA presented at 47th EASD

VIVUS, Inc. today announced that multiple abstracts were presented at the 47th European Association for the Study of Diabetes (EASD) Annual Meeting in Lisbon, Portugal. The presentations highlighted the long-term beneficial effects of QNEXA treatment in metabolically-impaired patients with prediabetes, diabetes, and metabolic syndrome.

17 Sep 2011

DARA's KRN5500 meets primary end-points in Phase II study for chemotherapy-induced neuropathic pain

Thanks to greater awareness, earlier detection and improving therapeutic agents, people with cancer are living longer than ever before. One of the consequences of living longer is the symptom burden of cancer survivorship, which may have a substantial impact on quality of life for many survivors. One such burden is the pain syndromes resulting from cancer treatments.

17 Sep 2011

BARDA awards Vaxin $21.7M contract to accelerate development of novel anthrax vaccine

Vaxin Inc., a clinical stage vaccine development company, today announced that it has been awarded a contract valued at up to $21.7 million by the Office of Biomedical Advanced Research and Development Authority (BARDA) for pre-clinical assessment, final manufacturing process development and the supply of clinical materials to support an IND filing and first-in-man dose ranging study of the company's proprietary anthrax vaccine, AdVAV.

17 Sep 2011

ONGLYZA used with insulin maintains improvement in glucose control in adults with type 2 diabetes

Bristol-Myers Squibb Company and AstraZeneca today announced results from an investigational Phase 3b clinical study in which the addition of ONGLYZA (saxagliptin) 5 mg to ongoing insulin therapy (with or without metformin) maintained reductions of blood sugar levels (glycosylated hemoglobin levels, or HbA1c) in adult patients with type 2 diabetes compared to the addition of placebo (with or without metformin) from 24 to 52 weeks.

16 Sep 2011

Linagliptin demonstrates durable reductions in blood glucose for T2D adults

Boehringer Ingelheim and Eli Lilly and Company today announced results of a 102 week Phase III study for linagliptin, which show meaningful and durable reductions in blood glucose for adults with type 2 diabetes.

16 Sep 2011

Combination of prasugrel plus ASA can treat acute coronary syndrome

In order to better prevent blood clots, the drugs clopidogrel or prasugrel can be prescribed to patients with acute ischaemia of the heart muscle, in addition to acetylsalicylic acid.

16 Sep 2011

Anavex announces ANAVEX pre-clinical data on Alzheimer's disease

Anavex Life Sciences Corp. will present the most recent data showing the therapeutic potential of ANAVEX compounds in animal models of Alzheimer's disease at a special symposium of the 34th annual meeting of the Japan Neuroscience Society.

16 Sep 2011

Potential new treatment for fragile X syndrome

Researchers at Vanderbilt University Medical Center, in collaboration with Seaside Therapeutics in Cambridge, Mass., have achieved a milestone in the development of a potential new treatment for fragile X syndrome, the most common genetic cause of autism.

16 Sep 2011

Shorter treatment with telaprevir-based combination regimen may benefit hepatitis C patients

Treatment with a telaprevir-based combination regimen for hepatitis C - heretofore a chronic, destructive and difficult to manage disease - effectively can be shortened to six months in about two-thirds of patients, finds a new study published Thursday in the New England Journal of Medicine.

16 Sep 2011

Experimental malaria vaccine shows positive results among children in small Burkina Faso study

"An experimental malaria vaccine tested on children in Burkina Faso has shown 'a high level of efficacy' in protecting against the disease, a study published in" Thursday's New England Journal of Medicine said, according to Agence France-Presse.

16 Sep 2011

Probiotics appear to protect against upper respiratory tract infections

Taking probiotics seems to provide both children and adults with a mild degree of protection against many upper respiratory tract infections (URTI) including the common cold, according to a new systematic review. People who consume probiotics are also less likely to end up taking antibiotics for an upper respiratory infection, the review found.

16 Sep 2011

Azithromycin gel may treat borreliosis in humans

Blood-sucking ticks are not just a nuisance, they can also transmit dangerous diseases. One of them is Lyme disease, which is caused by bacteria of the genus Borrelia, and requires a course of treatment with antibiotics lasting several weeks. LMU researchers have come up with a quicker alternative.

16 Sep 2011

Diclofenac in nano-formulated doses provides effective pain relief

A novel formulation of diclofenac provides pain relief at lower-than-standard doses during a Phase II clinical study as reported today at the 2011 World Congress on Osteoarthritis.

16 Sep 2011

CRF announces late breaking trials & first report investigations to be presented at TCT 2011

The Cardiovascular Research Foundation has announced the late breaking trials and first report investigations that will be presented at the Transcatheter Cardiovascular Therapeutics (TCT) 2011 scientific symposium. Presented in partnership with the American College of Cardiology (ACC), TCT 2011 is the world’s leading educational meeting specializing in interventional cardiovascular medicine and will take place November 7-11, 2011 in San Francisco.

15 Sep 2011

Anavex Life Sciences to present data on lead compound for Alzheimer’s at Japan Neuroscience Society

Anavex Life Sciences Corp. will present the most recent data showing the therapeutic potential of ANAVEX compounds in animal models of Alzheimer’s disease at a special symposium of the 34th annual meeting of the Japan Neuroscience Society. The symposium is being held in Yokohama, Japan from September 15-17, 2011.

15 Sep 2011

International patient groups anxiously await start of Huntington’s trial

Prana Biotechnology Limited received a very positive reaction from international patient groups and researchers at this week’s World Congress on Huntington’s Disease in Melbourne. The company had a major presence at the Congress and the Prana team has held numerous meetings and conversations with patient groups and researchers.

15 Sep 2011

KAI enters KAI-4169 development and commercialization agreement with Ono

KAI Pharmaceuticals, Inc., a privately held drug discovery and development company, today announced the signing of an agreement with Ono Pharmaceutical Co., Ltd. for the development and commercialization in Japan of KAI-4169, KAI's lead product candidate.

15 Sep 2011

Cempra's solithromycin demonstrates efficacy comparable to levofloxacin for CABP treatment

Cempra Pharmaceuticals today announced results from its Phase II clinical trial investigating the efficacy, safety and tolerability of oral administration of our fourth generation macrolide, solithromycin (CEM-101), a fluoroketolide antibiotic, in comparison with oral levofloxacin for the treatment of community-acquired bacterial pneumonia (CABP).

15 Sep 2011

Drug Trial News

Novartis reports positive results from first pivotal ACZ885 Phase III trial in systemic juvenile idiopathic arthritis

Additional data on safety, tolerability of Cempra's solithromycin to be presented at 51st ICAAC

Multiple abstracts on QNEXA presented at 47th EASD

DARA's KRN5500 meets primary end-points in Phase II study for chemotherapy-induced neuropathic pain

BARDA awards Vaxin $21.7M contract to accelerate development of novel anthrax vaccine

ONGLYZA used with insulin maintains improvement in glucose control in adults with type 2 diabetes

Linagliptin demonstrates durable reductions in blood glucose for T2D adults

Combination of prasugrel plus ASA can treat acute coronary syndrome

Anavex announces ANAVEX pre-clinical data on Alzheimer's disease

Potential new treatment for fragile X syndrome

Shorter treatment with telaprevir-based combination regimen may benefit hepatitis C patients

Experimental malaria vaccine shows positive results among children in small Burkina Faso study

Probiotics appear to protect against upper respiratory tract infections

Azithromycin gel may treat borreliosis in humans

Diclofenac in nano-formulated doses provides effective pain relief

CRF announces late breaking trials & first report investigations to be presented at TCT 2011

Anavex Life Sciences to present data on lead compound for Alzheimer’s at Japan Neuroscience Society

International patient groups anxiously await start of Huntington’s trial

KAI enters KAI-4169 development and commercialization agreement with Ono

Cempra's solithromycin demonstrates efficacy comparable to levofloxacin for CABP treatment

How agentic AI is reshaping laboratory workflows

Fourier 80: bringing benchtop NMR systems to the laboratory

How industrial hygiene flow calibration supports defensible exposure data

Latest News